<DOC>
	<DOCNO>NCT01585350</DOCNO>
	<brief_summary>The purpose study learn effect experimental vaccine ( MELITAC 12.1 ) combine substance call lipopolysaccharide ( LPS ; endotoxin ) , polyICLC , Montanide ISA-51 . The LPS , polyICLC , Montanide ISA-51 include vaccine test whether effect MELITAC 12.1 vaccine . The study also look whether experimental vaccine drug cause change immune system .</brief_summary>
	<brief_title>A Multipeptide Vaccine Plus Toll-Like Receptor Agonists Melanoma Patients</brief_title>
	<detailed_description>Goals : 1 . To determine safety intradermal subcutaneous injection lipopolysaccharide ( LPS ) vaccine adjuvant multipeptide vaccine . 2 . To obtain preliminary data whether administration multipeptide vaccine plus 2 TLR agonist immunogenic without Incomplete Freund 's Adjuvant ( IFA ) 3 . To obtain preliminary data whether addition either 2 toll-like receptor ( TLR ) agonists improve persistence circulate CD8+ T cell response vaccination multipeptide vaccine . 4 . To determine local systemic toxicity administration multipeptide vaccine 2 TLR agonist , without incomplete Freund 's adjuvant . 5 . To determine cytokine chemokine profile vaccine-site microenvironment week 1 injection multipeptide vaccine 2 TLR agonist , without IFA . 6 . To obtain preliminary data T cell activation status apoptosis vaccine site microenvironment ( VSME ) function vaccine adjuvant . 7 . To assess whether circulate CD8 T cell induced vaccination express different home receptor profile ( CLA , CXCR3 , α4β1 integrin , α4β7 integrin ) . 8 . To evaluate dendritic cell activation function sentinel immunize node drain site vaccination , production IDO , arginase , IL10 , IL12 . 9 . To characterize MyD88 expression dendritic cell infiltrate vaccination site . 10 . To identify regulatory process vaccination site . Design : This open-label , randomize , pilot study cellular molecular event cutaneous site immunization multipeptide vaccine . This related peptide vaccine associate immunologic efficacy majority participant associate clinical tumor regression participant . The maximum number participant accrue 51 . Endpoints : Primary : - Safety , measure adverse event , locally systemically - CD8+ CD4+ peptide-reactive T cell response among lymphocyte peripheral blood sentinel immunize node ( SIN ) Secondary : - Toll-like receptor signal replicate immunization site - CCR integrin expression vaccine induce T cell peripheral blood replicate immunization site - Th1 , Th2 , Th17 profile T cell vaccination site SIN measure cytokine expression ( IFNγ , IL-2 , TNFα , IL-4 , IL-5 , IL-10 , IL-17 , IL-23 ) , nuclear expression transcription factor ( T-bet , GATA3 , RORγt ) immunohistochemistry . - Chemokines CXCL9 , 10 , 11 ; CCL19 , CCL21 , CXCL12 , CXCL13 vaccine site microenvironment . - Markers activation , regulation , apoptosis CD4 CD8 T cell vaccine site SIN : CD69 , Ki67 , FoxP3 , TUNEL stain . - Homing receptor express antigen-reactive ( tetramer-positive ) T cell induced vaccination , circulation SIN . - MyD88 expression VSME SIN - Regulatory process immunization site SIN - Regulatory T cell ( CD4+CD25hi FoxP3+ ) - Myeloid suppressor cell - Indole-amine dioxygenase - PD-1 , B7-H1 - IL-10 IL-12 expression dendritic cell ( DC )</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Poly ICLC</mesh_term>
	<mesh_term>Freund 's Adjuvant</mesh_term>
	<criteria>Histologically cytologically proven melanoma meet one follow two criterion : Stage IIBIV melanoma render clinically free disease surgery , therapy , spontaneous remission within 6 month prior registration . Stage III IV melanoma disease . Patients may eligible definite equivocal finding persistent metastatic disease long finding meet RECIST criterion measurable disease . Patients brain metastasis may eligible follow true : The total number brain metastasis ever less equal 3 . The brain metastases completely remove surgery treat completely stereotactic radiotherapy . Stereotactic radiotherapy , gamma knife , use 1 week prior study entry . There evident growth brain metastasis since treatment . No treated brain metastasis great 2 cm diameter time protocol entry . Patients must least two intact axillary and/or inguinal lymph node basin . All patient must : ECOG performance status 0 1 . Ability willingness give inform consent . Laboratory parameter follow : HLAA1 , A2 , A3 , A11 , A31 ANC &gt; 1000/mm3 Platelets &gt; 100,000/mm3 Hgb ≥ 9 g/dL AST ALT ≤ 2.5 x upper limit normal ( ULN ) Bilirubin ≤ 2.5 x ULN Alkaline Phosphatase ≤ 2.5 x ULN Creatinine ≤ 1.5 x ULN HIV negative Hepatitis C negative HGBA1C level &lt; 7 % Patients brain metastasis , unless meet inclusion criterion Patients currently receive systemic cytotoxic chemotherapy , radiation , experimental therapy , receive therapy within precede 4 week . Gamma knife stereotactic radiosurgery may administer within prior 4 week , must administer less one week prior study enrollment . Patients currently receive nitrosoureas receive therapy within precede 6 week . Patients clinically detectable melanoma deem likely investigator require intervention first 12 week study would require premature discontinuation . Patients know suspected allergy component vaccine . Patients receive follow medication study entry within precede 4 week exclude : Agents putative immunomodulating activity ( exception nonsteroidal antiinflammatory agent topical steroid Allergy desensitization injection . Systemic corticosteroid , administer parenterally orally . Inhaled steroid ( e.g . Advair® , Flovent® , Azmacort® ) permit . Topical corticosteroid acceptable , include steroid low solubility administer nasally local effect ( e.g . Nasonex® ) . Any growth factor ( e.g . GMCSF , GCSF , erythropoietin ) . Interferon therapy . Interleukin2 interleukins . Tolllike receptor agonist , include imiquimod resiquimod . Prior melanoma vaccination may exclusion criterion circumstance : Patients recur progressed either administration melanoma vaccine may eligible enroll 12 week follow last vaccination . Patients may vaccinate previously peptide vaccine ( except may vaccinate peptide include MELITAC 12.1 MELITAC 12.6 ) Patients may vaccinate protein , DNA , cellbased vaccine include protein peptide derive . Other investigational drug investigational therapy patient currently take drugs/therapy , receive drugs/therapy within 1 month . Pregnancy possibility become pregnant vaccine administration . Women must also breast feeding . Patients medical contraindication potential problem complying requirement protocol , opinion investigator . Patients classified Class III IV heart disease accord New York Heart Association Body weight &lt; 110 lbs No active prior autoimmune disorder require cytotoxic immunosuppressive therapy , autoimmune disorder visceral involvement . The following exclusionary : The presence laboratory evidence autoimmune disease ( e.g . positive ANA titer ) without associate symptom Clinical evidence vitiligo Other form depigmenting illness Mild arthritis require NSAID medication medical therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>melanoma</keyword>
	<keyword>peptide vaccine</keyword>
	<keyword>polyICLC</keyword>
	<keyword>lipopolysaccharide ( LPS )</keyword>
	<keyword>immunotherapy</keyword>
</DOC>